Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics

Executive Summary

Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.

You may also be interested in...



Glaxo Discussing Lotronex DTC Advertising In Context Of Safety Concerns

Glaxo Wellcome is continuing to discuss a potential Lotronex direct-to-consumer advertising campaign with FDA as the company and the agency work on the risk management program for the irritable bowel syndrome product.

Glaxo Discussing Lotronex DTC Advertising In Context Of Safety Concerns

Glaxo Wellcome is continuing to discuss a potential Lotronex direct-to-consumer advertising campaign with FDA as the company and the agency work on the risk management program for the irritable bowel syndrome product.

Lotronex Advisory Committee Will Discuss Program For Ischemic Colitis Risk

A risk management program to track postmarketing incidences of ischemic colitis with Glaxo Wellcome's Lotronex will be discussed at the June 27 meeting of FDA's Gastrointestinal Drugs Advisory Committee.

Related Content

UsernamePublicRestriction

Register

PS035595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel